Elite Pharmaceuticals, Inc. reported significant financial improvements in its latest 10-Q filing for the three and nine months ended December 31, 2025. The company achieved total revenue of $31.6 million for the third quarter, a substantial increase of 120% compared to $14.4 million in the same period last year. For the nine-month period, revenue reached $108.1 million, more than double the $52.0 million reported for the same timeframe in 2024. The gross profit for the third quarter was $12.9 million, up from $6.1 million a year earlier, while the nine-month gross profit also saw a significant rise to $54.3 million from $22.8 million.
The company’s net income for the third quarter was $18.6 million, a turnaround from a net loss of $10.9 million in the prior year. For the nine months, Elite Pharmaceuticals reported a net income of $26.4 million, compared to a net loss of $21.3 million in the same period of 2024. This improvement in profitability is attributed to increased manufacturing fees, which surged to $31.4 million for the third quarter, compared to $13.7 million in the previous year, reflecting a strong demand for its products.
In terms of operational developments, Elite Pharmaceuticals has seen a notable increase in its current assets, which rose to $96.8 million as of December 31, 2025, compared to $57.7 million at the end of March 2025. This increase was driven by higher accounts receivable and inventory levels, indicating a growing customer base and product demand. The company’s cash position also improved significantly, with cash and restricted cash totaling $21.6 million, up from $11.8 million at the beginning of the fiscal year. The total liabilities increased to $46.1 million from $42.9 million, primarily due to higher accounts payable and accrued expenses.
Strategically, Elite Pharmaceuticals has focused on expanding its product offerings and enhancing its manufacturing capabilities. The company has paused further development of New Drug Applications (NDAs) and is concentrating on its Abbreviated New Drug Applications (ANDAs), which are expected to drive future revenue growth. The company’s management has indicated that they are optimistic about the continued demand for their generic pharmaceutical products and anticipate further growth in the upcoming quarters. The outlook remains positive as the company aims to leverage its improved financial position and operational efficiencies to capitalize on market opportunities.
About ELITE PHARMACEUTICALS INC /NV/
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and manufacturing oral, controlled-release, and generic drugs. It owns a broad portfolio of approved generic products across various therapeutic categories, utilizing proprietary technology and strategic licensing agreements. The company emphasizes product development, manufacturing, and licensing to serve healthcare providers and patients in the U.S. and abroad, with a focus on high-barrier-to-entry generics and abuse-deterrent formulations.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.